Its not something you want to do over and over again
[DOI] [PMC free article] [PubMed] [Google Scholar] 128
However, the robustness of the evidence differs markedly: data are extensive for obesity, more limited and heterogeneous for BED, and extremely sparse for BN
Putting agonist activity at all three receptors into a single molecule is a relatively new pharmacology, and retatrutide is the lead compound exploring it
GLP-1 RAs are being studied [archived link] for use in many other medical conditions, including fatty liver disease, Parkinsons disease, and substance use disorders, among others
Before doing this, I believe its important to explain what a GLP-1 is, why it solves obesity, and the differences between orals and injectables (with their nuances)